Review Article

Targeting caspase-2 interactions with tau in Alzheimer’s disease and related dementias

STEFFEN POCKES a, b, c, MICHAEL A. WALTERS b, KAREN H. ASHE c, ∗∗

a Institute of Pharmacy, University of Regensburg, Regensburg, Germany
b Department of Medicinal Chemistry, Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, Minnesota
c Department of Neurology, University of Minnesota, Minneapolis, Minnesota

ARTICLE INFO

Targeting amyloid-β plaques and tau tangles has failed to provide effective treatments for Alzheimer’s disease and related dementias (ADRD). A more fruitful pathway to ADRD therapeutics may be the development of therapies that target common signaling pathways that disrupt synaptic connections and impede communication between neurons. In this review, we present our characterization of a signaling pathway common to several neurological diseases featuring dementia including Alzheimer’s disease, frontotemporal dementia, Lewy body dementia, and Huntington’s disease. This signaling pathway features the cleavage of tau by caspase-2 (Casp2) yielding Δtau314 (Casp2/tau/Δtau314). Through a not yet fully delineated mechanism, Δtau314 catalyzes the mislocalization and accumulation of tau to dendritic spines leading to the internalization of AMPA receptors and the concomitant weakening of synaptic transmission. Here, we review the accumulated evidence supporting Casp2 as a druggable target and its importance in ADRD. Additionally, we provide a brief overview of our initial medicinal chemistry explorations aimed at the preparation of novel, brain penetrant Casp2 inhibitors. We anticipate that this review will spark broader interest in Casp2 as a target for restoring synaptic dysfunction in ADRD.

INTRODUCTION

The promise of discovering better treatments for Alzheimer’s disease and related dementias (ADRD), among the most feared and frequent causes of debilitation in the elderly, has eluded the valiant efforts of researchers worldwide. One reason for the lack of progress is that available interventions do not treat the underlying pathophysiological mechanisms of these diseases, targeting putative pathological triggers rather than the processes that mediate their detrimental effects on the brain. Another reason is the recent recognition that most patients with dementia have multiple pathologies, potentially tempering the effects of single-target therapies. Therefore, the ability to target a unique signaling pathway that is present in multiple diseases is an increasingly important but unmet medical need. The development of therapies that repair synaptic connections and restore communication between neurons in the brain will undoubtedly improve the treatment of ADRD. There is an urgent need for better treatments since available interventions do not address the underlying mechanisms of these diseases.

Multiple experimental therapies targeting fibrillar amyloid-β (Aβ) plaques and tau tangles have failed to produce robust results. The tau protein undergoes a variety of posttranslational modifications in ADRD, resulting in the formation of tau fibrils.1,2 However, fibrillar tau has been dissociated from neuronal death and network dysfunction, implicating nonfibrillar species in mediating cognitive abnormalities.3,4 Targeting the nonfibrillar forms of Aβ and tau that are diffusely distributed throughout the brain, alone or in combination with antifibril therapies, may be a more successful strategy.

Caspase-2 – Role and function

Caspases (cysteine-dependent aspartate-directed proteases) are a group of proteases that cleave target proteins after aspartic acid

Abbreviations: AD, Alzheimer’s disease; ADRD, Alzheimer’s disease and related dementias; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; APP, amyloid precursor protein; ASO, antisense oligonucleotide; Aγ, amyloid-β; BACE, β-site cleaving enzyme; CARD, caspase recruitment domain; Casp, caspase; Dab, 2,4-diaminobutyric acid; DED, death effector domain; FTD, frontotemporal dementia; HD, Huntington’s disease; LBD, Lewy body dementia; logP, logarithmic value of the partition coefficient; LTD, long-term depression; MDM2, mouse double minute 2 homolog; mEPSC, miniature excitatory synaptic current; PD, Parkinson’s disease; PDD, Parkinson’s disease with dementia; PS, presenilin; PTM, post-translational modification; SAR, structure-affinity relationship; Δtau314, tau cleavage product; TPSA, topological polar surface area

*Reprint requests Steffen Pockes, Institute of Pharmacy, University of Regensburg, Universitätsstrasste 31, 93053 Regensburg, Germany
**Karen H. Ashe, Department of Neurology, University of Minnesota, 2101 6th Street SE, Minneapolis, MN, 55455

E-mail addresses: steffen.pockes@ur.de, spockes@umn.edu (S. POCKES), mwalters@umn.edu (M.A. WALTERS), hslao@umn.edu (K.H. ASHE).

https://doi.org/10.1016/j.trsl.2022.10.009
Received 22 July 2022; Revised 26 October 2022; Accepted 30 October 2022

1931-5244/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Please cite this article as: S. POCKES et al., Targeting caspase-2 interactions with tau in Alzheimer’s disease and related dementias, Translational Research (2022), https://doi.org/10.1016/j.trsl.2022.10.009
residues. They originally evolved to mediate apoptosis, a form of programmed cell death. Interestingly, caspases have evolved in vertebrates to also play multiple roles in brain function including synaptic plasticity, dendritic development, learning and memory. Caspases can be subdivided into 3 groups: initiator caspases (eg, caspase-2, -8, -9, -10), effector caspases (eg, caspase-3, -6, -7) and inflammatory caspases (eg, caspase-1, -4, -5). All caspases are synthesized as inert zymogens or pro-caspases. Initiator caspases are activated by the assembly of zymogens into multicomponent complexes triggered by an intrinsic apoptotic pathway via cellular stress or an extrinsic apoptotic pathway by extracellular ligands via cell surface death receptors. Thus primed, the initiator caspases activate effector caspases by cleaving their corresponding zymogens.

The activated effector caspases go on to degrade specific sets of proteins from among several hundred caspase-sensitive cell proteins to induce apoptosis.

Caspase-2 (Casp2) is a highly conserved caspase. Casp2 participates in apoptosis triggered by a variety of stimuli, such as endoplasmic reticulum stress, metabolic stress, and DNA damage to name but a few. This is observed in the periphery in the process of adipocyte apoptosis which manifests as metabolic syndrome. Casp2 deficiency protected mice from diet-induced obesity, the metabolic syndrome, and nonalcoholic steatohepatitis or nonalcoholic fatty liver disease (NASH/NAFLD). In the central nervous system, Casp2 mediates retinal ganglion cell death, synaptic weakening, neurodegeneration due to ischemic damage, and the decrease in spine density found in neuronal cultures from a mouse model of AD. This panoply of roles has captured the attention of researchers and spurred interest in Casp2 as an exciting and promising drug target.

Two observations may temper enthusiasm for inhibiting Casp2: (1) Cascade-2 knockout mice displaying the complete absence of Casp2 results in aging-related loss of bone mass; (2) Casp2 can act as a tumor suppressor in some mouse models. Arguing in favor of the safety of inhibiting Casp2 are the observations that mice carrying null mutations for Casp2 are viable and devoid of severe phenotypic abnormalities, which manifests as metabolic syndrome. Casp2 deficiency protected mice from diet-induced obesity, the metabolic syndrome, and nonalcoholic steatohepatitis or nonalcoholic fatty liver disease (NASH/NAFLD). In the central nervous system, Casp2 mediates retinal ganglion cell death, synaptic weakening, neurodegeneration due to ischemic damage, and the decrease in spine density found in neuronal cultures from a mouse model of AD. This panoply of roles has captured the attention of researchers and spurred interest in Casp2 as an exciting and promising drug target.

Two observations may temper enthusiasm for inhibiting Casp2: (1) Cascade-2 knockout mice displaying the complete absence of Casp2 results in aging-related loss of bone mass; (2) Casp2 can act as a tumor suppressor in some mouse models. Arguing in favor of the safety of inhibiting Casp2 are the observations that mice carrying null mutations for Casp2 are viable and devoid of severe phenotypic abnormalities, which manifests as metabolic syndrome. Casp2 deficiency protected mice from diet-induced obesity, the metabolic syndrome, and nonalcoholic steatohepatitis or nonalcoholic fatty liver disease (NASH/NAFLD). In the central nervous system, Casp2 mediates retinal ganglion cell death, synaptic weakening, neurodegeneration due to ischemic damage, and the decrease in spine density found in neuronal cultures from a mouse model of AD. This panoply of roles has captured the attention of researchers and spurred interest in Casp2 as an exciting and promising drug target.

Caspases are activated by Aβ and caspase-2 has been shown to be required for Aβ1-42-induced cell death. These activated caspases cleave the neuronal protein tau, which is abnormally processed in AD. Caspase cleavage of tau is attributed mainly to Casp2, Casp3 and Casp6 producing tau fragments that have been shown in experimental models to induce neurodegeneration (Fig 1). However, it was recently demonstrated that Casp6 cleaved tau generates tau aggregates that may be neuroprotective. Casp2 was directly implicated as a key driver of synaptic dysfunction in J20 APP transgenic mice. This was proposed to be by activation of the RhoA/ROCK-II signaling pathway that leads to the collapse of dendritic spines via cleavage of ROCKII.

Fig 1 shows a cartoon schematic of 2N/4R tau, indicating known sites of caspase cleavage. For clarity, post-translational modifications and cleavage by other proteases are not shown. Five sites of cleavage are known though there may be others that have not yet been detected. The tetrameric acidic sequences for each of these sites are shown, along with a classification of the site as being a canonical sequence for Casp2.

The cleavage of tau to give Δtau314 occurs at a noncanonical site for Casp2. We have shown that this fragment of tau is nonfibrillar, most likely because this cleavage is proximal to PHF6 which is considered essential for tau self-assembly. It is not known why this site is especially sensitive to Casp2 cleavage but binding of tau outside Casp2’s active site (exosites) may facilitate this cleavage; (2) Two other caspase cleavage sites are located near the N-terminus of tau and are canonical for both Casp6 and Casp3 cleavage. (4) Notably, caspase cleavage at D348 is not observed, even though this sequence is canonical for both Casp2 and Casp3 (and noncanonical for other caspases). It is possible that this proteolysis, and that at D13 and D25 occurs but is followed by other cleavage events that make it nonobservable.

Caspase-2 and tau in Alzheimer’s disease and related dementias

Caspases are activated by Aβ and caspase-2 has been shown to be required for Aβ1-42-induced cell death. These activated caspases cleave the neuronal protein tau, which is abnormally processed in AD. Caspase cleavage of tau is attributed mainly to Casp2, Casp3 and Casp6 producing tau fragments that have been shown in experimental models to induce neurodegeneration (Fig 1). However, it was recently demonstrated that Casp6 cleaved tau generates tau aggregates that may be neuroprotective. Casp2 was directly implicated as a key driver of synaptic dysfunction in J20 APP transgenic mice. This was proposed to be by activation of the RhoA/ROCK-II signaling pathway that leads to the collapse of dendritic spines via cleavage of ROCKII.
Our findings in Zhao et al. suggest that tau and Casp2 form a toxic partnership.49 The 35kDa tau fragment generated when Casp2 cleaves tau at Asp314 (D314) enters the dendritic spine along with full-length tau, impairing synaptic function.55 The identification of D314 as the site at which Casp2 cleaves tau to form Δtau314 was achieved by mass spectrometry.56 The ability of each of the eight known caspases expressed in the brain was also tested, and only Casp2 generated a 35-kDa tau fragment, presumably recognizing the noncanonical cleavage sequence YKPVD314 in tau.55 To verify the assumption that Casp2 cleaves tau at D314, a tau variant in which D314 was mutated to glutamate (D314E) was prepared and shown to resist Casp2 cleavage,56 firmly supporting the hypothesis that Δtau314 is formed when tau is cleaved by Casp2.

The presence of Δtau314 correlates inversely with memory function in tau transgenic mice and is elevated in humans with Alzheimer’s disease or mild cognitive impairment.55 Δtau314 reversibly impairs cognitive and synaptic function in animal and cellular models of tauopathies.55 The mislocalization and accumulation of tau in dendritic spines mediate synaptic dysfunction independent of neurodegeneration.50 In cell cultures, tau containing the P301L mutation (tauP301L) mislocalizes and accumulates in dendritic spines,57 the principal loci of excitatory neurotransmission and synaptic plasticity which underlie learning and memory. Tau mislocalization resulted in decreased synaptic transmission due to the reduction of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPAR) in the spines.50 When D314 was mutated to glutamate (D314E) to prevent caspase cleavage, tauP301L no longer mislocalized to spines.57 TauP301L also failed to mislocalize to spines in neurons cultured from Casp2 null mice.57 Conversely, recombinant Δtau314 did localize to spines even in neurons lacking Casp2.56 These data indicate that Casp2 catalyzes the mislocalization and accumulation of mutant tau and the reduction of AMPAR in spines, and also excludes the possibility that other proteases besides Casp2 induce tau mislocalization.

Under physiological conditions, Casp2 reduces functional AMPAR in dendritic spines leading to long-term depression (LTD).54 LTD is a form of synaptic plasticity that weakens excitatory neurotransmission and underlies the physiological process of forgetting, an essential component of normal cognition that is carefully regulated by neural signals (Fig 2).51 Recent studies of human brain specimens in our group have revealed elevated levels of Casp2 and Δtau314 not only in AD,55,56 but also in Parkinson’s disease with dementia (PDD),53 Lewy body dementia (LBD),54 Huntington’s disease55 and frontotemporal dementia (FTD); here Δtau314 levels were elevated in the brains of rTg4510 (Zhao et al.) and rT2 mice (Steuer et al.), while levels in human brain specimens have not yet been reported.55,56 (Fig 3). The elevated levels of Casp2 in these conditions suggest that the physiological Casp2-LTD signaling pathway57 is co-opted and overstimulated by pathological triggers in several neurodegenerative conditions, leading to excessive synaptic weakening and dementia. While neural signals activate the physiological Casp2-LTD pathway, the precise triggers that activate the pathological Casp2-LTD pathway are unknown. Ubiquitous features of neurodegenerative disorders such as oxidative stress, ER stress, and DNA damage have been shown to activate Casp2 and could contribute to its dysregulation.14-18 Under pathological conditions, the attenuation of excitatory postsynaptic neurotransmission is mediated by excessive Casp2 cleavage of tau leading to the accumulation of tau and reduction of AMPAR in dendritic spines. Whether the cleavage of tau by Casp2 plays a role in physiological LTD remains to be investigated. The hyperactivation of
Casp2 strengthens excitatory neurotransmission resulting in unregulated forgetting (Fig 3).

Taken together, these results demonstrate that the pathological fragment Δtau314 from Casp2 cleavage of tau may be associated with synaptic dysfunction and dementia in multiple diseases.

Targeting caspase-2 by developing selective inhibitors

The identification of Casp2 cleavage of tau as a common mediator of synaptic dysfunction and dementia augments the significance and importance of developing Casp2 inhibitors. From a medicinal chemistry perspective, extensive efforts are still needed to accelerate the discovery of effective drugs. Although several studies on Casp2 inhibitors have been published in recent years,11,56,57 elementary features such as oral availability and brain penetration have not yet been achieved. Our initial studies on the development of selective Casp2 inhibitors followed an approach based on the canonical but unselective Casp2 inhibitor AcVDVDAD-CHO and the tau cleavage sequence YKPVD314.58 A set of 35 pentapeptide ligands provided helpful insights into structure-affinity relationships (SAR) and achieved maximum selectivity with AcVDV (Dab)D-CHO (pKᵢ (Casp2) = 7.26) by introducing the amino acid Dab (2,4-diaminobutyric acid) at position 2 (selectivity factor of ~30 over Casp3).58 Surprisingly, the pentapeptide AcYKPVD-CHO, derived from the tau cleavage site, showed no affinity for either Casp2 or Casp3.58 By systematically exchanging individual amino acid positions, the amino acid lysine at P4 and proline at P3 were thought to be responsible for this lack of activity.58

The development and expression of a series of recombinant tau mutants in an in vitro cleavage assay were consistent with these medicinal chemistry findings.58 In the search for new lead structures with excellent Casp2 selectivity and drug suitability, another approach was taken by our groups in Bresinsky et al.12 This approach featured the investigation of inhibitors based on cleavage sites specific to Casp2 in proteins other than tau.59 The cleavage sequences of Golgin-160,60 the protein transport protein Sec16A,61 transcription regulatory factor 1,61 Golgin-160, the Ral GTPase-activating protein subunit alpha-1,61 the Holliday junction recognition protein,61 and mouse double minute 2 homolog (MDM2, human and mouse)62 were selected based on the reported specificity of Casp2 cleavage and the pentapeptides AcGESPD-CHO, AcWDRAD-CHO, AcQDTRD-CHO, AcADRTD-CHO, AcLDVPD-CHO, and AcITVKD-CHO were prepared.59 This extended peptide series included another 53 new molecules, predominantly truncated tetra- and tripeptides, but which did not demonstrate enhanced Casp2 selectivity or affinity. These results support the hypothesis that a five amino acid motif is required for efficient Casp2 inhibition.59 The inhibitors AcLDVPD-CHO (pKᵢ (Casp2/cpCasp2) = 7.88/7.66) and AcFDVDP-CHO (pKᵢ (Casp2/cpCasp2) = 8.15/8.03) derived from mouse and human MDM2, respectively, showed the highest affinity for Casp2 but no selectivity for Casp2 over Casp3.59 The pentapeptide AcITVKD-CHO was the only inhibitor derived from natural cleavage sequences that exhibited some selectivity for Casp2 (2-fold selectivity) with moderate affinity (pKᵢ (Casp2) = 6.40) and, interestingly, does not contain an aspartic acid at position P4.59 Crystal structures (Casp3) of AcTVD(Dab)D-CHO derived from an expanded AcTVKD-CHO-series confirmed that the P4-Thr is a good isostere for the P4-Asp and causes little change in protein conformation.59

Our subsequent study (Singh et al.) went a step further, incorporating peptidomimetic moieties and unnatural amino acids with the aim of obtaining more bioavailable structures.63 To achieve this goal, known structural elements which enhanced selectivity and efficacy from...
previous SAR studies were combined. In addition, S-33q (Fig 4) and R-33q, the pure P2 epimers of the previously published racemic 33q, were synthesized and pharmacologically characterized. While R-33q did not demonstrate significant affinity for Casp2 and Casp3, S-33q exhibited significant affinity for Casp2 ($pK_i = 7.89$) with 70-fold Casp2/Casp3 selectivity. Alterations at amino acid positions P4 and P5 resulted in compound 3 (Fig 4) which had 794-fold Casp2 selectivity over Casp3 and Casp2 activity in the double-digit nanomolar range ($pK_i = 7.40$). Further modification of the reactive warhead from aldehyde to nitrile at position P1 to improve pharmacokinetic and -dynamic properties led to compound 1 (Fig 4) which exhibited high affinity ($pK_i$ (Casp2) = 8.12) and a promising selectivity profile in an in vitro caspase panel assay (123-fold selective towards Casp3 and $>2,000$-fold selective towards Casp1, 6, 7, 9) and only weak activity towards the proteolytic enzymes thrombin and cathepsin B ($IC_{50} = 18,620$ nM, selectivity $>1,600$-fold). The low activity relative to other cysteine proteases like cathepsin B is another promising feature for this class of inhibitors, regarding their specificity. Fig 5 shows the computationally predicted covalent docking (CovDock, Schrödinger) of compound 1 with the Casp2 apo-structure (ligand removed) from PDB:1PYO. Key interactions are shown. Although the aldehyde warhead is a prominent feature of the recently approved drug voxelotor for the treatment for sickle cell anemia and was an excellent warhead in our early SAR studies, this reactive group is often considered undesirable due to its high electrophilicity and susceptibility to oxidative metabolism. In contrast, nitrile-based covalent inhibitors have also been clinically validated, are known for their safety and efficacy in humans (eg, nimotretinir a covalent inhibitor of the SARS-CoV-2 main protease), and have been used successfully in other caspase inhibitors. Compound 1 is a covalent reversible Casp2 inhibitor with stronger potency and higher specificity than previously reported inhibitors. More advanced biological assays confirmed that compound 1 effectively inhibits Casp2-mediated cleavage of tau and blocks the production of $\Delta$tau314. Using cultured rat and mouse hippocampal neurons expressing tauP301S (a commonly used model of frontotemporal dementia), it was demonstrated that compound 1 prevented the disproportionate accumulation of tauP301S in dendritic spines. Lastly, in an experimental electrophysiological setup, it was shown that expression of tauP301S impairs postsynaptic function of excitatory synapses, as determined by recording mEPSCs, and that compound 1 completely normalizes mEPSCs and rescues synaptic function. These results indicate that Casp2 mediates its pathological effects catalytically, paving the way for further efforts to develop small molecule Casp2 inhibitors to treat ADRD. Indeed, this structural evolution will be necessary because, given the high molecular weight (674.74 Da) and high TPSA (218.03 Å$^2$) of compound 1, we do not expect it to enter the brain in significant amounts with these physicochemical properties.

**Summary & outlook**

The targeting of tau tangles in the treatment of ADRD has thus far been unsuccessful, warranting efforts to target other forms of tau. We expect that targeting the formation of $\Delta$tau314, a soluble fragment of tau, may be more fruitful. Several lines of evidence in humans and mice validate Casp2 as a target: (1) Lowering Casp2 improves memory, synaptic function and neurodegeneration in mouse models of four neurodegenerative disorders – Alzheimer’s disease (AD), Huntington’s disease (HD) (newly recognized as a tauopathy), Parkinson’s disease (PD), and frontotemporal dementia (FTD); (2) In mice modeling FTD, reducing Casp2 levels $\sim35\%$ (using a morpholino ASO) lowers brain levels of the pathological tau fragment, $\Delta$tau314, and reverses memory deficits within 6 weeks: Unfortunately, our attempts to produce ASO as therapeutics were clouded by unexpected challenges of toxicity. (3) Lowering Casp2 levels in these mice before neurons have died normalizes memory function; (4) Even when 50% of hippocampal CA1 neurons have died, lowering Casp2 levels partially restores memory function; (5) Casp2-resistant mutant tau with a D314E mutation delays memory loss and neurodegeneration in transgenic mice modeling FTD; (6) Brain levels of Casp2 and $\Delta$tau314 are elevated in patients with AD, PD, HD, and LBD.

In vitro systems used to elucidate the underlying pathophysiological mechanisms of in vivo observations have shown that: (1) Tau accumulates and AMPAR are reduced in the dendritic spines of cultured primary neurons expressing mutant tau, but these processes do not occur in neurons lacking Casp2; (2) Compound 1 prevents the accumulation of tau and reduction of AMPAR in the dendritic spines of mutant tau-expressing neurons; (3) Rendering tau resistant to Casp2 maintains AMPAR in the dendritic spines of neurons from mouse models of FTD.

The Casp2-LTD signaling pathway is a natural pathway that is dysregulated, rather than a potential artifact of an experimental disease model, as is the case in transgenic rodents with supra-abundant amyloid plaque deposition. It is therefore likely to be present in humans and clinically relevant. Because Casp2-LTD is a normal pathway, the
misactivated pathway is likely not an unintended artifact of our experimental ADRD models, minimizing the possibility that a Casp2 inhibitor will target a mechanism that does not exist or plays only a minor role in the pathogenesis of actual ADRD in humans. In aggregate, these in vivo and in vitro findings suggest that uncontrolled, pathological activation of the Casp2/tau/Δtau314 signaling pathway markedly weakens excitatory neurotransmission and exaggerates forgetting, and that a Casp2 inhibitor will improve synaptic function and cognition in patients with mild and moderate ADRD. Targeting the Casp2/tau/Δtau314 pathway can prevent and reverse cognitive decline.4,5,20 One exciting clinical implication is that a Casp2 inhibitor might not only improve the ability to learn and remember new information, but also recover lost memories by fortifying the synapses in engrams that are suppressed by reductions in AMPAR.7,8 We predict that Casp2 inhibitors have the potential to improve dementia in Alzheimer’s disease and several related dementias, which is an increasingly important consideration given that most patients have more than one pathology.51–53

Several improvements of current Casp2 inhibitors are needed. Foremost is bioavailability, specifically orally administered and brain penetrant Casp2 inhibitors that restore synaptic function and reverse memory deficits in mouse models of ADRD. Our findings thus far play an important role in the design of new peptidomimetic inhibitors. It is unlikely that we can design these compounds solely based on adherence to Lipinski’s Rule of 5 (molecular weight, logP, hydrogen bond donors/acceptors, TPSA, rotatable bonds).84 Challenges to blood-brain barrier penetration have been overcome in the area of kinase inhibitors which have been a notoriously difficult class of compounds to target to the brain.85 Additionally, the development of Casp2 inhibitors as prodrug compounds may be another promising approach; brain penetrant caspase inhibitors are that prodrugs already exist. For example, TRP601/ORPHA133563 (Fig 4), an irreversible inhibitor of Casp3 and Casp2 that is a prodrug of Δ2Me-TRP601 (IC50 (Casp2) = 7.4 nM, IC50 (Casp3) = 0.42 nM), protects the newborn rodent brain against excitotoxicity, hypoxia-ischemia, and perinatal arterial stroke with a 6-hour therapeutic time window and no adverse effects on physiological parameters.86 Furthermore, TRP601 did not significantly modify the activity of a broad panel of enzyme, peptide and nonpeptide receptors, nuclear receptors, ion channels or amine transporters at 10 μM.86 When administered intravenously (i.v.), TRP601 (1 mg/kg) rapidly entered the brain in adult rats (Tmax = 25 minutes; Cmax = 120 ng/mL), and no TRP601-related cytotoxic effects were observed when administered i.v. to adult dogs at doses up to 3 mg/kg/d for 14 days.86 Another example is VX-765 (Belnaacasan) (Fig 4), an orally absorbed prodrug of desetyl-VX-765 (VRT-043198), a reversible covalent, potent Casp1 inhibitor.64,87 VX-765 has been tested in two phase II clinical trials (treatment resistant VRT-043198), a reversible covalent, potent Casp1 inhibitor.64,87

Overall, the biological data for Casp2 as a target in ADRD is clear and compelling, and the medicinal chemistry advances for the development of Casp2 inhibitors are promising for eventual use in clinical trials. Given the ever-increasing number of patients with ADRD, intensive research in this area is a vital and critical goal.

NOTES

The authors are founders and shareholders of Myriel, Inc.

ACKNOWLEDGMENTS

Conflict of Interest: All authors have read the journal’s authorship statement. The authors disclosed all potential conflicts of interests. All authors have read the journal’s policy on disclosure of potential conflicts of interest and have disclosed any financial or personal relationship with organizations that could potentially be perceived as influencing the described research.

The authors were supported by NIH Grant R01AG0623199 (Ashe, Walters), R01AG60766 (Ashe), Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, Forschstipendium 436921318, Pockes), ADDF-Harrington Scholar Award (Repairing Neurotransmission in Alzheimer’s Disease and Related Disorders by Targeting Caspase-2, Ashe), Lucas Brothers Foundation (Caspase-2 Inhibitors to Reverse Cognitive Decline, Ashe).

The manuscript has been reviewed by and approved by all named authors. The authors thank Jessica Fuller for her contribution regarding Fig 5.

REFERENCES

17. Kumar S. Caspase 2 in apoptosis, the DNA damage response and tumour suppression: enigma or no more? Nat Rev Cancer 2009;9:897.


